ArticleScientific reports2026
Sinensetin attenuates post-stroke depression via dual modulation of TLR4/NF-κB-NRF2/GPX4 pathways.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis in major depressive disorder: Molecular mechanisms, cellular vulnerability, and therapeutic opportunities.Biochemistry and biophysics reports · 2026Review
- Iron dyshomeostasis and its neurobiological mechanisms in psychiatric disorders.Molecular psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Post-stroke depression (PSD) is a complex neuropsychiatric complication driven by neuroinflammation and ferroptosis, yet effective therapies remain limited. Sinensetin (SIN), a polymethoxylated flavone derived from citrus fruits, possesses potent anti-inflammatory and antioxidant properties. However, its therapeutic efficacy and underlying mechanisms in PSD have not been explored. To investigate this, a mouse model of PSD was established by combining photothrombotic stroke with low-dose lipopolysaccharide (LPS) administration. Mice were treated with SIN (25 and 50 mg/kg) for 14 days. Depressive-like behaviors were assessed using the sucrose preference test (SPT), tail suspension test (TST), and forced swimming test (FST). Crucially, protein-level validation was performed using quantitative immunofluorescence (for glial activation) and ELISA (for serum cytokines and pathway markers), complemented by qPCR and molecular docking/dynamics (MD) simulations. SIN treatment significantly alleviated depressive-like behaviors and restored cerebral blood flow in PSD mice. Quantitative immunofluorescence and ELISA analyses revealed that SIN effectively suppressed the hyperactivation of microglia (IBA1) and astrocytes (GFAP) in the hippocampus and reduced serum concentrations of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). Mechanistically, SIN inhibited the TLR4/NF-κB signaling pathway by suppressing NF-κB nuclear translocation and concurrently activated the NRF2/GPX4 antioxidant axis, thereby mitigating lipid peroxidation and neuronal ferroptosis. Additionally, molecular docking and MD simulations predicted energetically favorable interactions between SIN and key targets (e.g., TLR4, KEAP1), providing supportive evidence for its multi-target mechanism. Our findings demonstrate that SIN exerts neuroprotective effects in PSD by dually modulating TLR4/NF-κB-mediated neuroinflammation and NRF2/GPX4-dependent ferroptosis. These results highlight SIN as a promising natural therapeutic candidate for the treatment of depression following stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.